Resveratrol suppresses NTHi-induced inflammation via up-regulation of the negative regulator MyD88 short

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Andrews, Carla S ^a   Matsuyama, Shingo ^a   Lee, Byung Cheol ^a   Li, Jian Dong ^a  

^a GEORGIA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84989329064     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep34445     Document Type: Article

References (42)

1. Olin, J. T. & Wechsler, M. E. Asthma: pathogenesis and novel drugs for treatment. BMJ. 349, g5517 (2014).
2. Brusselle, G. G., Joos, G. F. & Bracke, K. R. New insights into the immunology of chronic obstructive pulmonary disease. Lancet 378, 1015-1026 (2011).
3. Myers, T. R. & Tomasio, L. Asthma: 2015 and beyond. Respir. Care 56, 1389-1407 (2011).
4. Hassett, D. J., Borchers, M. T. & Panos, R. J. Chronic obstructive pulmonary disease (COPD): Evaluation from clinical, immunological and bacterial pathogenesis perspectives. J. Microbiol. 52, 211-226 (2014).
5. Ko, F. W., Lim, T. K., Hancox, R. J. & Yang, I. A. Year in review 2013: Chronic obstructive pulmonary disease, asthma and airway biology. Respirology 19, 438-447 (2014).
6. Erle, D. J. & Sheppard, D. The cell biology of asthma. J. Cell Biol. 205, 621-631 (2014).
7. Barbu, C., Iordache, M. & Man, M. G. Inflammation in COPD: pathogenesis, local and systemic effects. Rom. J. Morphol. Embryol. 52, 21-27 (2011).
8. Foxwell, A. R., Kyd, J. M. & Cripps, A. W. Nontypeable Haemophilus influenzae: pathogenesis and prevention. Microbiol. Mol. Biol. Rev. 62, 294-308 (1998).
9. Alikhan, M. M. & Lee, F. E. Understanding nontypeable Haemophilus influenzae and chronic obstructive pulmonary disease. Curr. Opin. Pulm. Med. 20, 159-164 (2014).
10. Schumacher, S. K. et al. Prevalence and genetic diversity of nontypeable haemophilus influenzae in the respiratory tract of infants and primary caregivers. Pediatr. Infect. Dis. J. 31, 145-149 (2012).
11. Ito, M. et al. Clonal spread of beta-lactamase-producing amoxicillin-clavulanate-resistant (BLPACR) strains of non-typeable Haemophilus influenzae among young children attending a day care in Japan. Int. J. Pediatr. Otorhinolaryngol. 74, 901-906 (2010).
12. Hirota, J. A. & Knight, D. A. Human airway epithelial cell innate immunity: relevance to asthma. Curr. Opin. Immunol. 24, 740-746 (2012).
13. Sohal, S. S., Ward, C., Danial, W., Wood-Baker, R. & Walters, E. H. Recent advances in understanding inflammation and remodeling in the airways in chronic obstructive pulmonary disease. Expert. Rev. Respir. Med. 7, 275-288 (2013).
14. Hallstrand, T. S. et al. Airway epithelial regulation of pulmonary immune homeostasis and inflammation. Clin. Immunol. 151, 1-15 (2014).
15. Proud, D. & Leigh, R. Epithelial cells and airway diseases. Immunol. Rev. 242, 186-204 (2011).
16. Kawai, T. & Akira, S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 11, 373-384 (2010).
17. Shuto, T. et al. Activation of NF-kappa B by nontypeable Hemophilus influenzae is mediated by toll-like receptor 2-TAK1-dependent NIK-IKK alpha /beta-I kappa B alpha and MKK3/6-p38 MAP kinase signaling pathways in epithelial cells. Proc. Natl. Acad. Sci. USA. 98, 8774-8779 (2001).
18. Mogensen, T. H. Pathogen recognition and inflammatory signaling in innate immune defenses. Clin. Microbiol. Rev. 22, 240-273 (2009).
19. Janssens, S., Burns, K., Tschopp, J. & Beyaert, R. Regulation of interleukin-1-and lipopolysaccharide-induced NF-kappaB activation by alternative splicing of MyD88. Curr. Biol. 12, 467-471 (2002).
20. Burns, K. et al. Inhibition of interleukin 1 receptor/Toll-like receptor signaling through the alternatively spliced, short form of MyD88 is due to its failure to recruit IRAK-4. J. Exp. Med. 197, 263-268 (2003).
21. Janssens, S., Burns, K., Vercammen, E., Tschopp, J. & Beyaert, R. MyD88s, a splice variant of MyD88, differentially modulates NFkappaB-and AP-1-dependent gene expression. FEBS Lett. 548, 103-107 (2003).
22. Andrews, C. S. et al. Nontypeable Haemophilus influenzae-induced MyD88 short expression is regulated by positive IKK? and CREB pathways and negative ERK1/2 pathway. PLoS One 10, e0144840 (2015).
23. Miyata, M. et al. Glucocorticoids suppress inflammation via the upregulation of negative regulator IRAK-M. Nat. Commun. 6, 6062 (2015).
24. Page, C. P. & Spina, D. Phosphodiesterase Inhibitors in the treatment of inflammatory diseases. Handb. Exp. Pharmacol. 204, 391-414 (2011).
25. Royce, S. G. et al. Resveratrol has protective effects against airway remodeling and airway hyperreactivity in a murine model of allergic airway disease. Pathobiol. Aging. Age Relat. Dis. 1, 10.3402/PBA.v1i0.7134 (2011).
26. Knobloch, J. et al. Resveratrol attenuates the release of inflammatory cytokines from human bronchial smooth muscle cells exposed to lipoteichoic acid in chronic obstructive pulmonary disease. Basic Clin. Pharmocol. Toxicol. 114, 202-209 (2014).
27. Lee, M. et al. Anti-inflammatory and anti-asthmatic effects of resveratrol, a polyphenolic stilbene, in a mouse model of allergic asthma. Int. Immunopharmacol. 9, 418-424 (2009).
28. Wood, L. G., Wark, P. A. & Garg, M. L. Antioxidant and anti-inflammatory effects of resveratrol in airway disease. Antioxid. Redox. Signal. 13, 1535-1548 (2010).
29. Britton, R. G., Kovoor, C. & Brown, K. Direct molecular targets of resveratrol: identifying key interactions to unlock complex mechanisms. Ann. N. Y. Acad. Sci. 1348, 124-133 (2015).
30. Kuroyanagi, G. et al. Resveratrol suppresses TGF -induced VEGF synthesis in osteoblasts: Inhibition of the p44/p42 MAPK and SAPK/JNK pathways. Exp. Ther. Med. 9, 2303-2310 (2015).
31. Kondoh, K. & Nishida, E. Regulation of MAP kinases by MAP kinase phosphotases. Biochim. Biophys. Acta. 1773, 1227-1237 (2007).
32. Liew, F. Y., Xu, D., Brint, E. K. & ONeill, L. A. Negative regulation of toll-like receptor-mediated immune responses. Nat. Rev. Immunol. 5, 446-458 (2005).
33. Lee, J. et al. Phosphodiesterase 4B mediates extracellular signal-regulated kinase-dependent up-regulation of mucin MUC5AC protein by Streptococcus pneumoniae by inhibiting cAMP-protein kinase A-dependent MKP-1 phosphatase pathway. J. Biol. Chem. 287, 22799-22811 (2012).
34. Susuki-Miyata, S. et al. Cross-talk between PKA-C and p65 mediates synergistic induction of PDE4B by roflumilast and NTHi. Proc. Natl. Acad. Sci. USA. 112, E1800-E1809 (2015).
35. Park, E. J. & Pezzuto, J. M. The pharmacology of resveratrol in animals and humans. Biochim. Biophys. Acta. 1852, 1071-1113 (2015).
36. Poulsen, M. M. et al. Resveratrol and inflammation: Challenges in translating pre-clinical findings to improved patient outcomes. Biochim. Biophys. Acta. 1852, 1124-1136 (2015).
37. Koga, T. et al. Tumor suppressor cylindramatosis acts a negative regulator for Streptococcus pneumoniae-induced NFAT signaling. J. Biol. Chem. 283, 12546-12554 (2008).
38. Jeon, K. I. et al. Vinpocetine inhibits NF-kappaB-dependent inflammation via a IKK-dependent but PDE-independent mechanism. Proc. Natl. Acad. Sci. 107, 9795-9800 (2010).
39. Wang, W. Y. et al. CYLD negatively regulates nontypeable Haemophilus influenzae-induced IL-8 expression via phosphatase MKP-1-dependent inhibition of ERK. PLoS One 9, e112516 (2014).
40. Jono, H. et al. Transforming growth factor-smad signaling pathway negatively regulates nontyypeable Haemophilus influenzaeinduced MUC5AC mucin transcription via mitogen-activated protein kinase (MAPK) phosphatase-1-dependent inhibition of p38 MAPK. J. Biol. Chem. 278, 27811-27819 (2003).
41. Lim, J. H. et al. Tumor suppressor CYLD acts as a negative regulator for non-typeable Haemophilus influeza-induced inflammation in the middle ear and lung of mice. PLoS One 10, e1032 (2007).
42. Lee, B.-C., Miyata, M., Lim, J. H. & Li, J. D. Deubiquitinase CYLD acts as a negative regulator for bacterium NTHi-induced inflammation by suppressing K63-linked ubiquitination of MyD88. Proc. Natl. Acad. Sci. 113, E165-E171 (2016).